What is Alumis Inc.'s market cap?

Alumis Inc. (ALMS) has a market capitalization of $3.9B and trades on XNAS.

What is Alumis Inc.'s revenue and profitability?

Alumis Inc. generated $8.4M in trailing twelve-month revenue with a net loss of $237.4M, representing a net margin of -2825.7%, with free cash flow of -$377.0M. These figures are based on the Q1 2026 filing.

Who are Alumis Inc.'s competitors?

Alumis Inc.'s key competitors include Bristol-Myers Squibb, Takeda Pharmaceutical Company, Amgen, and others. These companies compete in similar markets and product categories.

Who does Alumis Inc. partner with?

Alumis Inc.'s notable partners include Foresite Labs.

What subsidiaries does Alumis Inc. have?

Alumis Inc.'s subsidiaries include ACELYRIN, Inc., Arrow Merger Sub, Inc..

Where is Alumis Inc. headquartered?

Alumis Inc. is headquartered in United States of America and employs approximately 147 people. It has been publicly traded since 2024.

Alumis Inc.

ALMS

Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases.

Market cap

$3.86B+952%

Revenue$8.4M—

Net income-$237.4M+30.9%

Free cash flow-$377.0M-28.8%

EPS (diluted)-$1.97+92.7%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 14, 2026

Revenue$1.7MMiss by $361.3K EPS-$0.74Miss by $0.01

Read the full report

Next report

Aug 12, 2026 (in a month)

Revenue estimate$3.6M

EPS estimate-$0.70

Financials

Q1 2026

Income statement

See full

Revenue$1.7M-90.0%

Operating income-$98.4M+3.1%

Net income-$93.1M+6.0%

EPS (diluted)-$0.74+59.3%

Balance sheet

See full

Cash & equivalents$63.9M-50.3%

Total debt$35.7M+1,881%

Total equity$567.0M+237%

Total assets$671.6M+157%

Cash flow

See full

Operating cash flow-$87.1M-8.4%

CapEx$164.0K+343%

Free cash flow-$87.2M-8.5%

Valuation & ratios

Valuation

See full

Market cap$3.86B+952%

Enterprise value$3.83B+1,578%

P/S459.8×—

Profitability

See full

Operating margin-5,364%—

Net margin-2,825.7%—

FCF margin-4,487.4%—

Returns & leverage

See full

Return on equity-64.6%—

Debt / equity0.1×+0.1×

Current ratio7.5×+3.8×

Segments

By segment

See full

Single Reportable$1.7M-90.0%

By product

See full

Collaboration Revenue$1.7M—

Competitors

By market cap

Amgen$196.25B+24.6%

Bristol-Myers Squibb$118.32B+25.1%

Oruka Therapeutics, Inc.$5.3B+970%

Alumis Inc.$3.9B+1,031%

Cullinan Therapeutics, Inc.$1.1B+158%

Avalo Therapeutics$1.0B+1,939%

Aclaris Therapeutics$797.5M+404%

Q32 Bio$213.5M+1,187%

By revenue growth

Amgen+9.1%

Bristol-Myers Squibb+1.8%

Aclaris Therapeutics-52.9%

By net margin

Amgen20.96%+3.6pp

Bristol-Myers Squibb15.01%+3.8pp

Cullinan Therapeutics, Inc.-346.14%—

Aclaris Therapeutics-832.58%-100pp

Alumis Inc.-2,825.7%—

Avalo Therapeutics-7,965.76%—

Profile

Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. The company leverages a proprietary precision data analytics platform to identify and develop small molecules and biologics that aim to replace broad immunosuppression with more precise target inhibition. Their lead programs focus on TYK2 inhibition and monoclonal antibodies for autoimmune and inflammatory conditions.

Competitive position

A clinical-stage innovator utilizing a proprietary data analytics platform to develop second-generation TYK2 inhibitors with optimized tolerability.

GeographiesUnited States

Customer segmentsPatients, Hospitals, Specialized clinics

Business modelR&D intensive, Drug development

SuppliersContract research organizations, Contract manufacturing organizations, Data analytics infrastructure providers

CustomersSpecialty distributors, Hospitals, Clinical trial participants

CountryUnited States of America

Listed2024

Employees147.0

CEOMartin Babler

SectorPHARMACEUTICAL PREPARATIONS

IndustryPHARMACEUTICAL PREPARATIONS

Websitealumis.com

FilingsSEC EDGAR

Ask your AI about Alumis Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alumis Inc.'s market cap?: Alumis Inc. (ALMS) has a market capitalization of $3.9B and trades on XNAS.
What is Alumis Inc.'s revenue and profitability?: Alumis Inc. generated $8.4M in trailing twelve-month revenue with a net loss of $237.4M, representing a net margin of -2825.7%, with free cash flow of -$377.0M. These figures are based on the Q1 2026 filing.
Who are Alumis Inc.'s competitors?: Alumis Inc.'s key competitors include Bristol-Myers Squibb, Takeda Pharmaceutical Company, Amgen, and others. These companies compete in similar markets and product categories.
Who does Alumis Inc. partner with?: Alumis Inc.'s notable partners include Foresite Labs.
What subsidiaries does Alumis Inc. have?: Alumis Inc.'s subsidiaries include ACELYRIN, Inc., Arrow Merger Sub, Inc..
Where is Alumis Inc. headquartered?: Alumis Inc. is headquartered in United States of America and employs approximately 147 people. It has been publicly traded since 2024.